You are here
By Jack Cush, MD | 08 April 2016
Dr. Jack Cush reviews the rheumatology highlights from the news, media, and journals from this past week:
- FDA Biosimilar Approval of Inflectra Viewed as a Milestone Advance in rheumatology and inflammatory diseases.
- Cardiology Anti-inflammatory Trial in post-MI patients with CV risk factors: given Losmapimod (p38MAPK inhibitor) but Fails to Improve CV Outcomes
- Severe Psoriasis Associated with a Renal Disease Risk
- Treating OA Knee Effusions with Low-Dose Spironolactone: results confirmed by Ultrasound.
- Midlife Plateau. Dr. Ronon Kavanagh of Galway, Ireland shares his experience in self/practice improvement by hiring a coach.
- Magnitude of visceral fat and liver fat is independently associated with hyperuricemia.
- Allopurinol use in hyperuricemia 7127 pts shows significant less major CV events (11%) & all-cause mortality (32%)
- CPK >1000: Causes in 192 pts-55% PM/DM, 17% drugs, 3% infx, 10% trauma, 12% idiopathic, 5% MI, 4%hypoT4, 2% metabolic
- Mayo study shows Cutaneous LE has 3 fold higher risk of CVA & 2 fold risk of PAD; 32% 20yr risk of Cardiovascular dz
- Sjogrens metanalysis of 4 RCTs, 276 pts shows Rituximab had no effect on Schirmers, fatigue, ESSDAI & SF36 @ wk24.
- Rheumatologists New Daily Practice Rules: 1) Give Hope, 2) Set Goals, 3) Establish the Rules. Pts will leave w/ certainty, not questions